Capricor Therapeutics Inc (NASDAQ:CAPR)’s share price reached a new 52-week low during mid-day trading on Wednesday . The stock traded as low as $0.85 and last traded at $0.90, with a volume of 100 shares changing hands. The stock had previously closed at $0.90.
CAPR has been the subject of several recent analyst reports. Zacks Investment Research lowered Capricor Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, September 6th. TheStreet raised Capricor Therapeutics from a “d” rating to a “c-” rating in a report on Tuesday, July 10th. Two investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $5.83.
Capricor Therapeutics (NASDAQ:CAPR) last announced its quarterly earnings data on Thursday, August 9th. The biotechnology company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.01). Capricor Therapeutics had a net margin of 111.24% and a negative return on equity of 204.82%. The firm had revenue of $0.40 million for the quarter, compared to the consensus estimate of $0.41 million. Analysts forecast that Capricor Therapeutics Inc will post -0.53 earnings per share for the current fiscal year.
Capricor Therapeutics Company Profile (NASDAQ:CAPR)
Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
Recommended Story: How Do You Make Money With Penny Stocks?
Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.